

is rising in BPDCN

Your guide to treatment
with **ELZONRIS®**
(tagraxofusp-erzs)

About ELZONRIS® (tagraxofusp-erzs)

ELZONRIS is a prescription medicine used to treat blastic plasmacytoid dendritic cell neoplasm (BPDCN) in adults and pediatric patients 2 years and older.

IMPORTANT SAFETY INFORMATION

ELZONRIS can cause serious side effects, including:

- **Capillary Leak Syndrome (CLS).** ELZONRIS can cause fluid to leak from small blood vessels into your body's tissues. This is called "Capillary Leak Syndrome." CLS can quickly cause you to have symptoms that may become life-threatening or fatal (ie, lead to death). **Get emergency medical help immediately if you develop any of the following symptoms:**
 - fast weight gain
 - swelling of your face, arms, hands, legs, or feet
 - shortness of breath or difficulty breathing
 - low blood pressure (dizziness or lightheadedness, headache, feeling tired, or shortness of breath)

Weigh yourself daily. Your healthcare provider will also check your weight and test your blood before you receive each dose of ELZONRIS and as needed during treatment.

Please see Important Safety Information, **including Boxed WARNING**, throughout this booklet and on pages 10-11, as well as accompanying Full Prescribing Information, **including Boxed WARNING**, for ELZONRIS to learn more.

 **ELZONRIS®**
(tagraxofusp-erzs) Injection

*Your guide to treatment with **ELZONRIS***

Your healthcare provider has chosen ELZONRIS to treat your BPDCN. This booklet provides you with helpful information and resources to help before and during your treatment.



Please see Important Safety Information, **including Boxed WARNING**, throughout this booklet and on pages 10-11, as well as accompanying Full Prescribing Information, **including Boxed WARNING**, for ELZONRIS to learn more.


What's in this booklet

Understanding BPDCN.....	4
What is ELZONRIS?.....	5
Your treatment with ELZONRIS.....	6
Sign up for patient support: Stemline ARC®.....	12
Helpful resources.....	13

Understanding BPDCN

What is BPDCN?

Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a cancer that affects your blood and the soft tissue inside your bones, which is called bone marrow. It can also affect other parts of your body, such as your lymph nodes, spleen, central nervous system, and skin.



How is BPDCN diagnosed?

To diagnose BPDCN, your healthcare provider will biopsy your skin, lymph nodes, or bone marrow. A biopsy means your healthcare provider will remove tissue from your skin, lymph nodes, or bone marrow, and look at it under a microscope.

One thing healthcare providers should look for in all of these tests is CD123, which is a type of protein found on BPDCN cells.

Please see Important Safety Information, **including Boxed WARNING**, throughout this booklet and on pages 10-11, as well as accompanying Full Prescribing Information, **including Boxed WARNING**, for ELZONRIS to learn more.

 **ELZONRIS**[®]
(tagraxofusp-erzs) Injection

What is ELZONRIS?



ELZONRIS is the only approved treatment for BPDCN. ELZONRIS is an IV (intravenous) infusion. A healthcare professional will administer ELZONRIS through a needle in your vein.

How does ELZONRIS work?


ELZONRIS works by finding and killing BPDCN cells. It is designed to target CD123, which is located on the surface of BPDCN cells, and cause cell death.

What is the goal of treatment?

The goal of treatment is to get rid of as many BPDCN cells as possible.

People respond differently to treatment with ELZONRIS. For some, ELZONRIS may get rid of all BPDCN cells in the body, while others may only get rid of some BPDCN cells in the body.

Some people can get a stem cell transplant as part of their treatment plan after ELZONRIS. Talk to your healthcare provider about what this means, and if this is a possibility for you.



IMPORTANT SAFETY INFORMATION (cont'd)

- **Hypersensitivity reactions** may occur with ELZONRIS. Symptoms may include rash, itching (pruritus), wheezing, or swelling in your face, including around your eyes and/or in and around your mouth

Please see Important Safety Information, **including Boxed WARNING**, throughout this booklet and on pages 10-11, as well as accompanying Full Prescribing Information, **including Boxed WARNING**, for ELZONRIS to learn more.

 **ELZONRIS**[®]
(tagraxofusp-erzs) Injection

Your treatment with *ELZONRIS*



Before you begin treatment

You will receive medicines about an hour before each ELZONRIS treatment to help reduce possible side effects of ELZONRIS. Talk to your treatment team if you have questions about these medicines.

Your treatment team will take blood for routine tests before each dose. This will also help them see how your blood, liver, and kidneys are working during treatment.

Your treatment team will also check your weight and vital signs before each dose. Vital signs are blood pressure, heart rate, temperature, and breathing rate.

IMPORTANT SAFETY INFORMATION (cont'd)

- **Liver damage** is usually detected through blood tests. Symptoms may include feeling tired (fatigue), loss of appetite, yellowing of your skin or the whites of your eyes (jaundice), or upper right abdominal pain or discomfort

Your healthcare provider will periodically test your blood while you are on ELZONRIS to check for liver damage.

Contact your healthcare provider immediately if you have any of these symptoms.

Getting medical treatment right away may help keep these problems from becoming more serious.

Please see Important Safety Information, **including Boxed WARNING**, throughout this booklet and on pages 10-11, as well as accompanying Full Prescribing Information, **including Boxed WARNING**, for ELZONRIS to learn more.

 **ELZONRIS**[®]
(tagraxofusp-erzs) Injection

Tell your treatment team about:



All of your medical conditions



All of the medicines you take, including prescription medicines, over-the-counter medicines, herbal supplements, and vitamins



ELZONRIS may harm your unborn baby. If there is a possibility that you may become pregnant during treatment, you should use birth control while you are on ELZONRIS, and for 1 week after the last dose.

ELZONRIS may cause fetal harm when administered to a pregnant woman. All pregnancies have a risk of birth defect, loss, or other adverse outcomes.

You should not breastfeed while you are on ELZONRIS. It is not known if ELZONRIS passes into breast milk.

Your treatment team will discuss your dosing schedule details with you

IMPORTANT SAFETY INFORMATION (cont'd)

If you have any side effects during treatment with ELZONRIS, your healthcare provider may hold your treatment for a period of time or completely stop your treatment with ELZONRIS.

Please see Important Safety Information, including **Boxed WARNING**, throughout this booklet and on pages 10-11, as well as accompanying Full Prescribing Information, including **Boxed WARNING**, for ELZONRIS to learn more.




ELZONRIS[®]
(tagraxofusp-erzs) Injection

During treatment with ELZONRIS



HOW:

Through a needle in your vein (IV infusion)



HOW LONG:

Each dose will take 15 minutes



HOW MUCH:

Your dose of ELZONRIS is based on your weight

Each cycle of ELZONRIS treatment is 21 days



You will receive ELZONRIS daily on days 1 to 5 of each treatment cycle. Your healthcare provider may decide to extend this dosing period up to day 10 of the treatment cycle.

- Your healthcare provider may delay a dose if your blood tests or vital signs show that it would be safer to wait. They may also decide it is safer to skip a dose
- You may have at least 10 days without treatment
- Your healthcare provider will then decide if and when you will receive another 21-day cycle of treatment

You will receive your first cycle of treatment in the hospital.

- Your treatment team will monitor your reaction to ELZONRIS for 24 hours after the last dose of cycle 1

Treatment cycle 2 and all additional treatment cycles may be in the hospital or in an outpatient clinic.

- Your treatment team should observe you for 4 hours after each dose

Keep all of your medical appointments

As with any medicine, it is important to follow the schedule set by your healthcare provider. If you miss an appointment, call your healthcare provider as soon as possible to reschedule.

Please see Important Safety Information, **including Boxed WARNING**, throughout this booklet and on pages 10-11, as well as accompanying Full Prescribing Information, **including Boxed WARNING**, for ELZONRIS to learn more.

 **ELZONRIS**[®]
(tagraxofusp-erzs) Injection

Watch your weight

Your weight gives your treatment team important information during your treatment. Fast weight gain can be a sign of CLS (capillary leak syndrome), a serious side effect.

- Weigh yourself daily, and write down your weight every day
- Weigh yourself at the same time every morning, without clothes, with the scale on a hard surface



Get emergency medical help immediately if you develop any of the following symptoms

- Fast weight gain
- Swelling of your face, arms, hands, legs, or feet
- Shortness of breath
- Low blood pressure (dizziness or lightheadedness, headache, feeling tired, or shortness of breath)

See page 13 of this booklet for a list of resources to help you during your treatment with ELZONRIS

IMPORTANT SAFETY INFORMATION (cont'd)

The most common side effects of ELZONRIS include CLS, nausea, feeling tired (fatigue), fever, swelling in your legs or feet, and weight gain.

These are not all of the possible side effects of ELZONRIS. If any new side effects start or an existing one gets worse, contact your healthcare provider immediately. For more information, talk to your treatment team.

Please see Important Safety Information, including **Boxed WARNING**, throughout this booklet and on pages 10-11, as well as accompanying Full Prescribing Information, including **Boxed WARNING**, for ELZONRIS to learn more.

 **ELZONRIS**[®]
(tagraxofusp-erzs) Injection

About ELZONRIS® (tagraxofusp-erzs)

ELZONRIS is a prescription medicine used to treat blastic plasmacytoid dendritic cell neoplasm (BPDCN) in adults and pediatric patients 2 years and older.

IMPORTANT SAFETY INFORMATION

ELZONRIS can cause serious side effects, including:

- **Capillary Leak Syndrome (CLS).** ELZONRIS can cause fluid to leak from small blood vessels into your body's tissues. This is called "Capillary Leak Syndrome." CLS can quickly cause you to have symptoms that may become life-threatening or fatal (ie, lead to death). **Get emergency medical help immediately if you develop any of the following symptoms:**

- fast weight gain
- swelling of your face, arms, hands, legs, or feet
- shortness of breath or difficulty breathing
- low blood pressure (dizziness or lightheadedness, headache, feeling tired, or shortness of breath)

Weigh yourself daily. Your healthcare provider will also check your weight and test your blood before you receive each dose of ELZONRIS and as needed during treatment.

- **Hypersensitivity reactions** may occur with ELZONRIS. Symptoms may include rash, itching (pruritus), wheezing, or swelling in your face, including around your eyes and/or in and around your mouth
- **Liver damage** is usually detected through blood tests. Symptoms may include feeling tired (fatigue), loss of appetite, yellowing of your skin or the whites of your eyes (jaundice), or upper right abdominal pain or discomfort

Your healthcare provider will periodically test your blood while you are on ELZONRIS to check for liver damage.

Contact your healthcare provider immediately if you have any of these symptoms.

Getting medical treatment right away may help keep these problems from becoming more serious.

Please see Important Safety Information, **including Boxed WARNING**, throughout this booklet and on pages 10-11, as well as accompanying Full Prescribing Information, **including Boxed WARNING**, for ELZONRIS to learn more.



If you have any side effects during treatment with ELZONRIS, your healthcare provider may hold your treatment for a period of time or completely stop your treatment with ELZONRIS.

The most common side effects of ELZONRIS include CLS, nausea, feeling tired (fatigue), fever, swelling in your legs or feet, and weight gain.

These are not all of the possible side effects of ELZONRIS. If any new side effects start or an existing one gets worse, contact your healthcare provider immediately. For more information, talk to your treatment team.

Be sure to tell your treatment team about:

- all of your medical conditions, including if you
 - are pregnant or plan to become pregnant. ELZONRIS may harm your unborn baby
 - If you are a female who can become pregnant, you should use effective birth control during ELZONRIS treatment and for 1 week after the last dose
 - Tell your healthcare provider right away if you become pregnant during treatment with ELZONRIS
 - are breastfeeding or plan to breastfeed. It is not known if ELZONRIS passes into breast milk. You and your healthcare provider should decide if you will receive ELZONRIS or breastfeed. You should not do both
- all of the medicines you take, including prescription medicines, over-the-counter medicines, vitamins, and herbal supplements

You can report any side effects to Stemline Therapeutics, Inc. at 1-877-332-7961 or contact the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Please see Full Prescribing Information, **including Boxed WARNING**, for ELZONRIS to learn more.

The risk information provided here is not comprehensive. To learn more, talk about ELZONRIS (tagraxofusp-erzs) with your healthcare provider or pharmacist.

The FDA-approved product labeling can be found accompanying this booklet.

Please see Important Safety Information, **including Boxed WARNING**, throughout this booklet and on pages 10-11, as well as accompanying Full Prescribing Information, **including Boxed WARNING**, for ELZONRIS to learn more.



Sign up for patient support: Stemline ARC®



You may be able to receive support by signing up for Stemline ARC. Talk to your treatment team about which programs you might be eligible for. They can guide you through the process.

ARC Patient Advocates provide a single point of contact



ARC Patient Advocates are here to provide ongoing support, connect you to helpful resources, and answer questions during your treatment journey. It's important to remember that ARC Patient Advocate support is not intended to replace discussions between you and your healthcare provider.

Here are some of the questions ARC Patient Advocates can help answer:

- How can I get financial assistance during my treatment?
- How can I get help with transportation or meals?
- How can I get coverage for ELZONRIS?
- How do I handle getting reimbursed by insurance?
- Where can I learn more about BPDCN?
- Where can I find mental health support?
- Where can I find patient, family, or caregiver support groups?
- What kind of resources can I find online?

For questions or more information about Stemline ARC, call 1-833-4-STEMLINE (1-833-478-3654) from 9:00 AM to 6:00 PM EST, Monday through Friday

Please see Important Safety Information, including **Boxed WARNING**, throughout this booklet and on pages 10-11, as well as accompanying Full Prescribing Information, including **Boxed WARNING**, for ELZONRIS to learn more.



Helpful resources

Resources are available to help you during your treatment. The resources below can give you more information about your cancer and its treatment.*

American Cancer Society®

cancer.org

CancerCare®

cancercare.org

Cancer Support Community

cancersupportcommunity.org

Leukemia & Lymphoma Society®

lls.org

National Cancer Institute

cancer.gov

National Organization for Rare Disorders

rarediseases.org

Use the links below to learn about the importance of eating nutritious food during your treatment, as well as for recipes and helpful hints.

American Cancer Society®

<https://www.cancer.org/healthy/eat-healthy-get-active.html>

National Cancer Institute

<https://www.cancer.gov/publications/patient-education/eatinghints.pdf>

Talk to your treatment team if you have
questions about your care

*Information provided by Stemline Therapeutics is meant for educational purposes only. It is not meant to replace your healthcare provider's medical advice or treatment. The organizations listed above are independent from Stemline Therapeutics. Stemline has listed these organizations only as a convenience and according to the permissions granted by their respective terms of use. Each organization has its own terms and conditions and privacy policy that should be reviewed if you choose to contact any of them.

Please see Important Safety Information, **including Boxed WARNING**, throughout this booklet and on pages 10-11, as well as accompanying Full Prescribing Information, **including Boxed WARNING**, for ELZONRIS to learn more.

 **ELZONRIS**[®]
(tagraxofusp-erzs) Injection

Talk to your treatment team

Write down any questions, comments, or concerns about BPDCN or ELZONRIS that you'd like to remember.

NOTES

Please see Important Safety Information, **including Boxed WARNING**, throughout this booklet and on pages 10-11, as well as accompanying Full Prescribing Information, **including Boxed WARNING**, for ELZONRIS to learn more.





*is rising
in BPDCN*

Please see Important Safety Information, **including Boxed WARNING**, throughout this booklet and on pages 10-11, as well as accompanying Full Prescribing Information, **including Boxed WARNING**, for ELZONRIS to learn more.

ELZONRIS® and Stemline ARC are registered trademarks of Stemline Therapeutics, Inc.
© 2025 – Stemline Therapeutics, Inc., a Menarini Group Company. Printed in USA.
All rights reserved. 03/25 MAT-US-TAG-00223

